Loading
Making CAR-T cells at or near the hospital instead of shipping cells to a central factory and back.
Academic centres (Sheba, Hospital Clínic Barcelona's ARI-0001, several Chinese and Indian programmes) and companies (Cellares 'Smart Factories', Orgenesis, Galapagos' decentralised model) manufacture cell therapies close to the patient, cutting vein-to-vein time to about a week and cost substantially. Regulators are working out how to license many small sites against one product specification.
Standardised closed platforms plus centralised quality oversight and digital batch records allow the same process to run at many sites.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
India's first home-grown CAR-T cell therapy, approved in 2023 for relapsed leukaemia and lymphoma, made in Mumbai for roughly a tenth of what the same kind of treatment costs in the US.
India's second approved CAR-T therapy, a Bengaluru-made version of a Spanish hospital's academic CD19 cell therapy, for lymphoma that has come back after other treatments.
Query for this technology: (TITLE:"Point-of-care and decentralised cell manufacturing" OR ABSTRACT:"Point-of-care and decentralised cell manufacturing") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Point-of-care and decentralised cell manufacturing, not a curated reading list.
Shares Vein-to-vein time and manufacturing slots, Autologous CAR-T manufacturing, batch by batch, CAR-T cell therapy and the tag supporting.
Shares Closed automated cell-therapy manufacturing, Autologous CAR-T manufacturing, batch by batch and the tag supporting.
Shares Closed automated cell-therapy manufacturing, Autologous CAR-T manufacturing, batch by batch, CAR-T cell therapy and the tag supporting.
Shares UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL, CAR-T cell therapy and the tag supporting.
Shares Closed automated cell-therapy manufacturing, Autologous CAR-T manufacturing, batch by batch and the tag supporting.
Shares Closed automated cell-therapy manufacturing and the tag supporting.
Shares Autologous CAR-T manufacturing, batch by batch, CAR-T cell therapy and the tag supporting.
Shares Autologous CAR-T manufacturing, batch by batch, CAR-T cell therapy and the tag supporting.